The focus of current therapies for T2D are treating hyperglycaemia via enhanced insulin production, which may be achieved via drugs such as sulphonylureas, or alternatively enhancing insulin sensitivity via medications such as metformin [43,44]. The gene discussed is INS; the disease is Hyperglycemia.